Corvus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Corvus Pharmaceuticals

28/03/2023 22:02

* Corvus Pharmaceuticals Inc  CRVS.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
December. The mean expectation of three analysts for the quarter
was for a loss of 23 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Corvus Pharmaceuticals Inc shares had fallen by 23.5% this
quarter.
    * The company reported a quarterly loss of $9.82 million.
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 28 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.23          -0.21          Beat
 Sep. 30 2022      -0.16          -0.32          Missed
 Jun. 30 2022      -0.18          -0.18          Met
 Mar. 31 2022      -0.15          -0.18          Missed